Kidney Week 2022

Orlando, Florida 03 November 2022 - 06 November 2022

Stopping RAS inhibitors does not slow eGFR decline in advanced CKD

16 Dec 2022 bởi

In patients with advanced chronic kidney disease (CKD), discontinuing renin–angiotensin system (RAS) inhibitor therapy does not slow down decline in estimated glomerular filtration rate (eGFR), a recent trial showed.

Stopping RAS inhibitors does not slow eGFR decline in advanced CKD

16 Dec 2022

Post hoc data boost voclosporin efficacy for severe lupus nephritis

14 Dec 2022 bởi

In the post hoc analysis of the AURORA 1 and 2 trials, the novel calcineurin inhibitor voclosporin was effective in achieving complete renal response (CRR)* in individuals with severe lupus nephritis** (LN).

Post hoc data boost voclosporin efficacy for severe lupus nephritis

14 Dec 2022

Potassium monitoring device ups QoL in dialysis patients

12 Dec 2022 bởi

Using a real-time potassium monitoring device saves money and improves quality of life (QoL) in haemodialysis patients in a study presented at Kidney Week 2022.

Potassium monitoring device ups QoL in dialysis patients

12 Dec 2022

CV benefits of dapagliflozin evident regardless of baseline kidney function

11 Dec 2022 bởi

The cardiovascular (CV) benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is evident regardless of baseline kidney function, according to an analysis of the DELIVER* trial presented at Kidney Week 2022.

CV benefits of dapagliflozin evident regardless of baseline kidney function

11 Dec 2022

Veverimer does not delay CKD progression

07 Dec 2022 bởi

Treatment with once-daily veverimer did not delay chronic kidney disease (CKD) progression, according to the results of the phase III VALOR-CKD trial.

Veverimer does not delay CKD progression

07 Dec 2022

DUET OLE supports long-term nephroprotection of sparsentan for FSGS patients

07 Dec 2022 bởi

Results from the open-label extension (OLE) period of the phase II DUET trial demonstrated the long-term nephroprotective potential and safety of sparsentan for individuals with focal segmental glomerulosclerosis (FSGS).

DUET OLE supports long-term nephroprotection of sparsentan for FSGS patients

07 Dec 2022

No CV benefits with cooler dialysate

27 Nov 2022 bởi

The use of a cooler dialysate during maintenance haemodialysis does not offer cardiovascular (CV) benefits to patients in the MyTEMP trial.

No CV benefits with cooler dialysate

27 Nov 2022